Skip to main content
Erschienen in: Strahlentherapie und Onkologie 10/2017

10.07.2017 | Original Article

Interobserver variability in target volume delineation of hepatocellular carcinoma

An analysis of the working group “Stereotactic Radiotherapy” of the German Society for Radiation Oncology (DEGRO)

verfasst von: E. Gkika, S. Tanadini-Lang, S. Kirste, P. A. Holzner, H. P. Neeff, H. C. Rischke, T. Reese, F. Lohaus, M. N. Duma, K. Dieckmann, R. Semrau, M. Stockinger, D. Imhoff, N. Kremers, M. F. Häfner, N. Andratschke, U. Nestle, A. L. Grosu, M. Guckenberger, T. B. Brunner

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Definition of gross tumor volume (GTV) in hepatocellular carcinoma (HCC) requires dedicated imaging in multiple contrast medium phases. The aim of this study was to evaluate the interobserver agreement (IOA) in gross tumor delineation of HCC in a multicenter panel.

Methods

The analysis was performed within the “Stereotactic Radiotherapy” working group of the German Society for Radiation Oncology (DEGRO). The GTVs of three anonymized HCC cases were delineated by 16 physicians from nine centers using multiphasic CT scans. In the first case the tumor was well defined. The second patient had multifocal HCC (one conglomerate and one peripheral tumor) and was previously treated with transarterial chemoembolization (TACE). The peripheral lesion was adjacent to the previous TACE site. The last patient had an extensive HCC with a portal vein thrombosis (PVT) and an inhomogeneous liver parenchyma due to cirrhosis. The IOA was evaluated according to Landis and Koch.

Results

The IOA for the first case was excellent (kappa: 0.85); for the second case moderate (kappa: 0.48) for the peripheral tumor and substantial (kappa: 0.73) for the conglomerate. In the case of the peripheral tumor the inconsistency is most likely explained by the necrotic tumor cavity after TACE caudal to the viable tumor. In the last case the IOA was fair, with a kappa of 0.34, with significant heterogeneity concerning the borders of the tumor and the PVT.

Conclusion

The IOA was very good among the cases were the tumor was well defined. In complex cases, where the tumor did not show the typical characteristics, or in cases with Lipiodol (Guerbet, Paris, France) deposits, IOA agreement was compromised.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31(13):1631–1639. doi:10.1200/JCO.2012.44.1659 CrossRefPubMed Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31(13):1631–1639. doi:10.​1200/​JCO.​2012.​44.​1659 CrossRefPubMed
3.
Zurück zum Zitat Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190(10):872–881. doi:10.1007/s00066-014-0714-1 CrossRefPubMed Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190(10):872–881. doi:10.​1007/​s00066-014-0714-1 CrossRefPubMed
4.
Zurück zum Zitat Verslype C, Rosmorduc O, Rougier P, Group EGW (2012) Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii41–48. doi:10.1093/annonc/mds225 CrossRefPubMed Verslype C, Rosmorduc O, Rougier P, Group EGW (2012) Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii41–48. doi:10.​1093/​annonc/​mds225 CrossRefPubMed
6.
Zurück zum Zitat Zijdenbos APDB, Margolin RA, Palmer AC (1994) Morphometric analysis of white matter lesions in MR images: method and validation. IEEE Trans Med Imaging 13(4):716–724CrossRefPubMed Zijdenbos APDB, Margolin RA, Palmer AC (1994) Morphometric analysis of white matter lesions in MR images: method and validation. IEEE Trans Med Imaging 13(4):716–724CrossRefPubMed
7.
Zurück zum Zitat Kelemen ASG, Gerig G (1999) Elastic model-based segmentation of 3‑D neuroradiological data sets. IEEE Trans Med Imaging 18(10):828–839CrossRefPubMed Kelemen ASG, Gerig G (1999) Elastic model-based segmentation of 3‑D neuroradiological data sets. IEEE Trans Med Imaging 18(10):828–839CrossRefPubMed
8.
Zurück zum Zitat Beddar AS, Briere TM, Balter P, Pan T, Tolani N, Ng C, Szklaruk J, Krishnan S (2008) 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol 87(3):445–448. doi:10.1016/j.radonc.2007.12.009 CrossRefPubMed Beddar AS, Briere TM, Balter P, Pan T, Tolani N, Ng C, Szklaruk J, Krishnan S (2008) 4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol 87(3):445–448. doi:10.​1016/​j.​radonc.​2007.​12.​009 CrossRefPubMed
9.
Zurück zum Zitat Hong TS, Bosch WR, Krishnan S, Kim TK, Mamon HJ, Shyn P, Ben-Josef E, Seong J, Haddock MG, Cheng JC, Feng MU, Stephans KL, Roberge D, Crane C, Dawson LA (2014) Interobserver Variability in Target Definition for Hepatocellular Carcinoma With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group Consensus Guidelines. Int J Radiat Oncol Biol Phys 89(4):804–813. doi:10.1016/j.ijrobp.2014.03.041 CrossRefPubMedPubMedCentral Hong TS, Bosch WR, Krishnan S, Kim TK, Mamon HJ, Shyn P, Ben-Josef E, Seong J, Haddock MG, Cheng JC, Feng MU, Stephans KL, Roberge D, Crane C, Dawson LA (2014) Interobserver Variability in Target Definition for Hepatocellular Carcinoma With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group Consensus Guidelines. Int J Radiat Oncol Biol Phys 89(4):804–813. doi:10.​1016/​j.​ijrobp.​2014.​03.​041 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kim YS, Kim JW, Yoon WS, Kang MK, Lee IJ, Kim TH, Kim JH, Lee HS, Park HC, Jang HS, Kay CS, Yoon SM, Kim MS, Seong J (2016) Interobserver variability in gross tumor volume delineation for hepatocellular carcinoma: Results of Korean Radiation Oncology Group 1207 study. Strahlenther Onkol 192(10):714–721. doi:10.1007/s00066-016-1028-2 CrossRefPubMed Kim YS, Kim JW, Yoon WS, Kang MK, Lee IJ, Kim TH, Kim JH, Lee HS, Park HC, Jang HS, Kay CS, Yoon SM, Kim MS, Seong J (2016) Interobserver variability in gross tumor volume delineation for hepatocellular carcinoma: Results of Korean Radiation Oncology Group 1207 study. Strahlenther Onkol 192(10):714–721. doi:10.​1007/​s00066-016-1028-2 CrossRefPubMed
11.
Zurück zum Zitat Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK (2003) Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 18(2):189–195. doi:10.1002/jmri.10336 CrossRefPubMed Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK (2003) Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 18(2):189–195. doi:10.​1002/​jmri.​10336 CrossRefPubMed
13.
Zurück zum Zitat European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943. doi:10.1016/j.jhep.2011.12.001 CrossRef European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943. doi:10.​1016/​j.​jhep.​2011.​12.​001 CrossRef
14.
Zurück zum Zitat Tsurusaki M, Sofue K, Isoda H, Okada M, Kitajima K, Murakami T (2016) Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol 51(1):71–79. doi:10.1007/s00535-015-1097-5 CrossRefPubMed Tsurusaki M, Sofue K, Isoda H, Okada M, Kitajima K, Murakami T (2016) Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol 51(1):71–79. doi:10.​1007/​s00535-015-1097-5 CrossRefPubMed
15.
Zurück zum Zitat Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, Zakher B, Pappas M, Graham E, Sullivan SD (2015) Imaging techniques for the diagnosis of Hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med 162(10):697–711. doi:10.7326/M14-2509 CrossRefPubMed Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, Zakher B, Pappas M, Graham E, Sullivan SD (2015) Imaging techniques for the diagnosis of Hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med 162(10):697–711. doi:10.​7326/​M14-2509 CrossRefPubMed
16.
Zurück zum Zitat Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, Kim YH, Han JK, Choi BI (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology 275(1):97–109. doi:10.1148/radiol.14140690 CrossRefPubMed Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, Kim YH, Han JK, Choi BI (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging – a systematic review and meta-analysis. Radiology 275(1):97–109. doi:10.​1148/​radiol.​14140690 CrossRefPubMed
17.
Zurück zum Zitat Heimbach J, Kulik LM, Finn R, Sirlin CB, Abecassis M, Roberts LR, Zhu A, Murad MH, Marrero J (2017) Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. doi:10.1002/hep.29086 Heimbach J, Kulik LM, Finn R, Sirlin CB, Abecassis M, Roberts LR, Zhu A, Murad MH, Marrero J (2017) Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. doi:10.​1002/​hep.​29086
18.
Zurück zum Zitat Nestle U, Rischke HC, Eschmann SM, Holl G, Tosch M, Miederer M, Plotkin M, Essler M, Puskas C, Schimek-Jasch T, Duncker-Rohr V, Ruhl F, Leifert A, Mix M, Grosu AL, Konig J, Vach W (2015) Improved inter-observer agreement of an expert review panel in an oncology treatment trial – Insights from a structured interventional process. Eur J Cancer 51(17):2525–2533. doi:10.1016/j.ejca.2015.07.036 CrossRefPubMed Nestle U, Rischke HC, Eschmann SM, Holl G, Tosch M, Miederer M, Plotkin M, Essler M, Puskas C, Schimek-Jasch T, Duncker-Rohr V, Ruhl F, Leifert A, Mix M, Grosu AL, Konig J, Vach W (2015) Improved inter-observer agreement of an expert review panel in an oncology treatment trial – Insights from a structured interventional process. Eur J Cancer 51(17):2525–2533. doi:10.​1016/​j.​ejca.​2015.​07.​036 CrossRefPubMed
19.
Zurück zum Zitat Schimek-Jasch T, Troost EG, Rucker G, Prokic V, Avlar M, Duncker-Rohr V, Mix M, Doll C, Grosu AL, Nestle U (2015) A teaching intervention in a contouring dummy run improved target volume delineation in locally advanced non-small cell lung cancer: Reducing the interobserver variability in multicentre clinical studies. Strahlenther Onkol 191(6):525–533. doi:10.1007/s00066-015-0812-8 CrossRefPubMed Schimek-Jasch T, Troost EG, Rucker G, Prokic V, Avlar M, Duncker-Rohr V, Mix M, Doll C, Grosu AL, Nestle U (2015) A teaching intervention in a contouring dummy run improved target volume delineation in locally advanced non-small cell lung cancer: Reducing the interobserver variability in multicentre clinical studies. Strahlenther Onkol 191(6):525–533. doi:10.​1007/​s00066-015-0812-8 CrossRefPubMed
Metadaten
Titel
Interobserver variability in target volume delineation of hepatocellular carcinoma
An analysis of the working group “Stereotactic Radiotherapy” of the German Society for Radiation Oncology (DEGRO)
verfasst von
E. Gkika
S. Tanadini-Lang
S. Kirste
P. A. Holzner
H. P. Neeff
H. C. Rischke
T. Reese
F. Lohaus
M. N. Duma
K. Dieckmann
R. Semrau
M. Stockinger
D. Imhoff
N. Kremers
M. F. Häfner
N. Andratschke
U. Nestle
A. L. Grosu
M. Guckenberger
T. B. Brunner
Publikationsdatum
10.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 10/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1177-y

Weitere Artikel der Ausgabe 10/2017

Strahlentherapie und Onkologie 10/2017 Zur Ausgabe

Review Article

“Radio-oncomics”

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.